Perfluorooctanoate exposure in a highly exposed community and parent and teacher reports of behaviour in 6-12-Year-old children

Paediatric and Perinatal Epidemiology

Volumn 28, Issue 2, 2014, Pages 146-156

  Stein, Cheryl R ^a   Savitz, David A ^b   Bellinger, David C ^c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

attention deficit disorders; child behaviour; epidemiology; fluorocarbons; perfluorooctanoic acid

Indexed keywords

PERFLUOROOCTANOIC ACID;

ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BEHAVIOUR ASSESSMENT SYSTEM FOR CHILDREN; BEHAVIOUR RATING INVENTORY OF EXECUTIVE FUNCTION; CHILD; CHILD BEHAVIOR; CONNER ADHD DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS IV SCALES; FEMALE; FLUID INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRESCHOOL CHILD; RATING SCALE; SCHOOL CHILD; SEX DIFFERENCE; WATER CONTAMINATION;

ATTENTION DEFICIT DISORDERS; CHILD BEHAVIOUR; EPIDEMIOLOGY; FLUOROCARBONS; PERFLUOROOCTANOIC ACID;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAPRYLATES; CHILD; CHILD DEVELOPMENT; DRINKING WATER; ENVIRONMENTAL EXPOSURE; EXECUTIVE FUNCTION; FEMALE; FLUOROCARBONS; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; NEUROPSYCHOLOGICAL TESTS; PARENTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEX DISTRIBUTION; WATER SUPPLY;

EID: 84893780850     PISSN: 02695022     EISSN: 13653016     Source Type: Journal    
DOI: 10.1111/ppe.12097     Document Type: Article

References (35)

1. US Environmental Protection Agency. Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers. Washington, DC: U.S. Environmental Protection Agency, 2009. Available at: http://www.epa.gov/oppt/pfoa/pubs/pfoainfo.html (accessed 1 March 2013).
2. US Environmental Protection Agency. Perfluorooctanoic Acid (PFOA). Washington, DC: U.S. Environmental Protection Agency, 2009. Available at: http://www.epa.gov/oppt/pfoa/index.html (accessed 1 March 2013).
3. Stahl T, Mattern D, Brunn H,. Toxicology of perfluorinated compounds. Environmental Sciences Europe 2011; 23: 1-52.
4. D'Eon JC, Mabury SA,. Is indirect exposure a significant contributor to the burden of perfluorinated acids observed in humans? Environmental Science & Technology 2011; 45: 7974-7984.
5. Kato K, Wong LY, Jia LT, Kuklenyik Z, Calafat AM,. Trends in Exposure to Polyfluoroalkyl Chemicals in the U.S. Population: 1999-2008 (dagger). Environmental Science & Technology 2011; 45: 8037-8045.
6. Jensen MS, Norgaard-Pedersen B, Toft G, Hougaard DM, Bonde JP, Cohen A, et al. Phthalates and perfluorooctanesulfonic acid in human amniotic fluid: temporal trends and timing of amniocentesis in pregnancy. Environmental Health Perspectives 2012; 120: 897-903.
7. Stein CR, Wolff MS, Calafat AM, Kato K, Engel SM,. Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: a pilot study. Reproductive Toxicology 2012; 34: 312-316.
8. Inoue K, Okada F, Ito R, Kato S, Sasaki S, Nakajima S, et al. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environmental Health Perspectives 2004; 112: 1204-1207.
9. Midasch O, Drexler H, Hart N, Beckmann MW, Angerer J,. Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. International Archives of Occupational and Environmental Health 2007; 80: 643-648.
10. Kuklenyik Z, Reich JA, Tully JS, Needham LL, Calafat AM,. Automated solid-phase extraction and measurement of perfluorinated organic acids and amides in human serum and milk. Environmental Science and Technology 2004; 38: 3698-3704.
11. So MK, Yamashita N, Taniyasu S, Jiang Q, Giesy JP, Chen K, et al. Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. Environmental Science & Technology 2006; 40: 2924-2929.
12. Tao L, Kannan K, Wong CM, Arcaro KF, Butenhoff JL,. Perfluorinated compounds in human milk from Massachusetts, U.S.A. Environmental Science & Technology 2008; 42: 3096-3101.
13. Volkel W, Genzel-Boroviczeny O, Demmelmair H, Gebauer C, Koletzko B, Twardella D, et al. Perfluorooctane sulphonate (PFOS) and perfluorooctanoic acid (PFOA) in human breast milk: results of a pilot study. International Journal of Hygiene and Environmental Health 2008; 211: 440-446.
14. Fei C, McLaughlin JK, Lipworth L, Olsen J,. Prenatal exposure to perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) and maternally reported developmental milestones in infancy. Environmental Health Perspectives 2008; 116: 1391-1395.
15. Fei C, Olsen J,. Prenatal exposure to perfluorinated chemicals and behavioral or coordination problems at age 7 years. Environmental Health Perspectives 2011; 119: 573-578.
16. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM,. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environmental Health Perspectives 2010; 118: 1762-1767.
17. Gump BB, Wu Q, Dumas AK, Kannan K,. Perfluorochemical (PFC) exposure in children: associations with impaired response inhibition. Environmental Science & Technology 2011; 45: 8151-8159.
18. Stein CR, Savitz DA,. Serum perfluorinated compound concentration and attention deficit/hyperactivity disorder in children 5-18 years of age. Environmental Health Perspectives 2011; 119: 1466-1471.
19. Stein CR, Savitz DA, Bellinger DC,. Perfluorooctanoate and neuropsychological outcomes in children. Epidemiology (Cambridge, Mass.) 2013; 24: 590-599.
20. Frisbee SJ, Brooks AP Jr, Maher A, Flensborg P, Arnold S, Fletcher T, et al. The C8 health project: design, methods, and participants. Environmental Health Perspectives 2009; 117: 1873-1882.
21. Flaherty JM, Connolly PD, Decker ER, Kennedy SM, Ellefson ME, Reagen WK, et al. Quantitative determination of perfluorooctanoic acid in serum and plasma by liquid chromatography tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2005; 819: 329-338.
22. Gioia GA,. BRIEF: Behavior Rating Inventory of Executive Function: Professional Manual. Odessa, FL: Psychological Assessment Resources, 2000.
23. Conners CK,. Conners' Rating Scales-Revised. North Tonawanda, NY: Multi-Health Systems, Inc., 2001.
24. Reynolds CR, Kamphaus RW,. BASC-2: Behavior Assessment System for Children: Manual. Minneapolis, MN: Pearson, 2004.
25. National Longitudinal Survey Program. U.S. Bureau of labor statistics. Available at: http://www.bls.gov/nls/nlsy97.htm (accessed 25 May 2012).
26. The Psychological Corporation. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Harcourt Brace and Company, 1999.
27. Rothman KJ, Greenland S,. Modern Epidemiology, 2nd edn. Philadelphia: Lippincott-Raven, 1998.
28. White SS, Fenton SE, Hines EP,. Endocrine disrupting properties of perfluorooctanoic acid. The Journal of Steroid Biochemistry and Molecular Biology 2011; 127: 16-26.
29. Briggs-Gowan MJ,. Discrepancies among mother, child, and teacher reports: examining the contributions of maternal depression and anxiety. Journal of Abnormal Child Psychology 1996; 24: 749-765.
30. Touliatos J,. Congruence of parents' and teachers' ratings of children's behavior problems. Journal of Abnormal Child Psychology 1981; 9: 347-354.
31. Phares V,. Perspectives on child behavior problems: comparisons of children's self-reports with parent and teacher reports. Psychological Assessment 1989; 1: 68-71.
32. Power MC, Webster TF, Baccarelli AA, Weisskopf MG,. Cross-sectional association between polyfluoroalkyl chemicals and cognitive limitation in the National Health and Nutrition Examination Survey. Neuroepidemiology 2012; 40: 125-132.
33. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ,. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicological Sciences: An Official Journal of the Society of Toxicology 2006; 92: 476-489.
34. Kapadia R, Yi JH, Vemuganti R,. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in Bioscience: A Journal and Virtual Library 2008; 13: 1813-1826.
35. Kaundal RK, Sharma SS,. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News & Perspectives 2010; 23: 241-256.